Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

About this update from Replimune Group, Inc.

[{"type":"text","content":"WOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2026.","length":348,"tagName":"p"},{"type":"text","content":"The Company has two abstracts selected for oral presentation, including a 3-year landmark overall survival analysis from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) plus nivolumab in anti-PD-1 failed melanoma, and an oral presentation on the final safety, efficacy, and biomarker results from the Phase 1 first-in-human study of RP2 alone and combined with nivolumab in advanced solid tumors. Four additional posters for RP1 and RP2 will be presented.","length":468,"tagName":"p"},{"type":"text","content":"Details for the presentations are as follows:","length":45,"tagName":"p"},{"type":"text","content":"Oral data presentations","length":23,"tagName":"p"},{"type":"text","content":"Abstract Title: A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti-PD-1-failed melanoma from the IGNYTE clinical trial.","length":156,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Session Title: Rapid Oral Abstract Session - Melanoma/Skin Cancers","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenter: Michael Wong, MD, PhD","length":32,"tagName":"p"}]},{"val":[{"type":"text","content":"Date: May 30, 2026, 5:30-5:36 pm CDT","length":36,"tagName":"p"}]},{"val":[{"type":"text","content":"Location: E451","length":14,"tagName":"p"}]},{"val":[{"type":"text","content":"Abstract #: 9518","length":16,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":164,"olType":false},{"type":"text","content":"Abstract Title: RP2 oncolytic immunotherapy alone and in combination with nivolumab (nivo) in patients with advanced solid tumors: Final safety, efficacy, and biomarker results from the phase 1 first-in-human (FIH) study.","length":221,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Session Title: Oral Abstract Session - Developmental Therapeutics-Immunotherapy","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenter: Joseph Sac...

More updates from Replimune Group, Inc.